B. Riley analyst Kyle Bauser raised the firm’s price target on LifeMD (LFMD) to $12 from $11 and keeps a Buy rating on the shares following the Q3 report.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFMD:
- LifeMD sees Q4 revenue $57M-$58M, consensus $57.34M
- LifeMD backs FY24 revenue view at least $205M, consensus $206M
- LifeMD reports Q3 EPS (14c), consensus (12c)
- LifeMD launches affiliated pharmacy to drive end-to-end patient care
- LifeMD launches TestoRx, direct to consumer testosterone replacement therapy